This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Autoimmune disease

Autoimmune disease

IL-17; serum/glucocorticoid regulated kinase 1 (SGK1)

Two independent studies suggest inhibiting SGK1 could help treat autoimmune diseases. In vitro, high salt concentrations promoted the differentiation of naïve human CD4+ cells into T helper type 17 (Th17) cells, induced IL-17 production and increased expression of SGK1. In a mouse model for experimental autoimmune encephalomyelitis (EAE), Sgk1-deficient animals had lower disease incidence and severity than nondeficient controls. Next steps could include testing the therapeutic effect of SGK1 inhibitors in models of Th17 cell-driven autoimmune diseases.

SciBX 6(13); doi:10.1038/scibx.2013.305
Published online April 4, 2013

Findings in first study unpatented; licensing status not applicable

Patent and licensing status for findings in second study unavailable

Kleinewietfeld, M. et al. Nature;
published online March 6, 2013;
doi:10.1038/nature11868
Contact: David A. Hafler, Yale School of Medicine, New Haven, Conn.
e-mail:
david.hafler@yale.edu
Contact: Markus Kleinewietfeld,
same affiliation as above
e-mail:
markus.kleinewietfeld@yale.edu

Wu, C. et al. Nature; published online March 6, 2013;
doi:10.1038/nature11984
Contact: Vijay K. Kuchroo, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.
e-mail:
vkuchroo@rics.bwh.harvard.edu
Contact: Aviv Regev, Broad Institute of MIT and Harvard, Cambridge, Mass.
e-mail:
aregev@broadinstitute.org